Gilead Sciences, Inc. (GILD) receives a “Buy” rating from analyst Courtney Breen of Bernstein with a price objective of $120. The approval of Yeztugo (Lenacapavir) by the FDA for HIV prevention is a key factor driving growth.

A strategic partnership between Gilead Sciences, Inc. (GILD) and the Global Fund aims to supply lenacapavir for HIV prevention. The drug’s innovative dosing paradigm may improve patient adherence and expand the PrEP market.

Impax Asset Management praises Gilead Sciences, Inc. (GILD) for its role in developing new medical treatments for chronic diseases. The company’s strong revenue from its HIV franchise and optimistic earnings guidance for the next fiscal year are noted.

While GILD is seen as a promising investment, other AI stocks may offer higher potential gains with lower risks. Investors looking for undervalued AI stocks can explore opportunities beyond Gilead Sciences, Inc.

Read more at Yahoo Finance: Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock